Meridiem Capital Partners LP Invests $11.51 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Meridiem Capital Partners LP bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 108,932 shares of the medical equipment provider's stock, valued at approximately $11,506,000. Meridiem Capital Partners LP owned about 0.05% of Zimmer Biomet as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Moore Capital Management LP purchased a new position in Zimmer Biomet in the 4th quarter valued at approximately $4,977,000. Lighthouse Investment Partners LLC purchased a new stake in Zimmer Biomet during the 4th quarter worth about $2,007,000. Jefferies Financial Group Inc. raised its position in Zimmer Biomet by 28.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 18,680 shares of the medical equipment provider's stock valued at $1,973,000 after purchasing an additional 4,133 shares in the last quarter. Humankind Investments LLC boosted its stake in shares of Zimmer Biomet by 4.2% in the 4th quarter. Humankind Investments LLC now owns 6,571 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 262 shares during the period. Finally, Gotham Asset Management LLC grew its position in shares of Zimmer Biomet by 386.7% during the fourth quarter. Gotham Asset Management LLC now owns 50,827 shares of the medical equipment provider's stock worth $5,369,000 after buying an additional 40,384 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.39% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH traded up $0.05 during trading hours on Friday, reaching $96.78. 2,339,193 shares of the company traded hands, compared to its average volume of 1,752,324. The stock has a market capitalization of $19.15 billion, a PE ratio of 21.75, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The stock has a fifty day simple moving average of $103.62 and a 200 day simple moving average of $105.92. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $121.30. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.94 earnings per share. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.99%. Zimmer Biomet's payout ratio is currently 21.24%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ZBH. JPMorgan Chase & Co. reduced their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Wells Fargo & Company dropped their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JMP Securities reduced their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Royal Bank of Canada dropped their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, Zimmer Biomet currently has an average rating of "Hold" and an average target price of $113.45.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.